House Rx Secures $30 Million in Financing to Improve the Specialty Pharmacy Experience for Patients and Their Care Teams

House Rx | March 15, 2022

House Rx, a health technology platform focused on improving affordability and patient access to specialty medications, announced it has secured $25 million in Series A financing led by Bessemer Venture Partners, bringing total funding to $30 million.

House Rx's technology platform and pharmacy service enable specialty practices to offer medically-integrated dispensing, which means patients can receive both their physician and pharmacy care from one team, collaborating on a unified technology platform. Since it launched in March 2021, House Rx has partnered with four medical specialty practices and 30 prescribers in California and Washington.

"We have a simple idea: partner with specialty clinics all over the country to enable medically integrated dispensing where the physician, pharmacist, nurses and techs can work together as one team, under one proverbial roof, to improve patient care. Our vision for the future of specialty pharmacy is a more local, more collaborative, and ultimately a more affordable system that leads to much better outcomes for patients."

Ogi Kavazovic, CEO and a co-founder

Specialty medications, which include treatments for cancers, rheumatic diseases and other chronic and acute conditions, are some of the most expensive drugs available. Unlike infused therapies which are administered in the clinics, the burden of specialty medication access and adherence often falls on patients, who typically need to battle several large bureaucracies to gain access to their medications. These often lead to multi-week delays in treatment and much lower adherence rates compared to medications administered in clinics.

Currently, specialty medications are mainly dispensed via mail by a patient's insurance company, not their doctor or a pharmacy a patient chooses. A growing body of research demonstrates that when patients obtain timely access to cancer treatments directly from their care team, they have better outcomes, including improved quality of life and increased survivability.

House Rx currently has over 30 employees, who are mostly software engineers and pharmacy operations. In addition to Bessemer Venture Partners, First Round Capital, Character.vc, and 1984.vc participated in the Series A funding. First Round Capital led the seed round as the initial investor alongside Khosla Ventures, Maverick Ventures, and 1984.vc. The funding from this latest round will go towards continued investments in House Rx's technology platform and scaling pharmacy operations.

"The specialty pharmacy market is in much need of a new approach - the current system severely lacks in patient choice and innovation, and we think House Rx's vision for a more modern, more decentralized approach will have incredible impact," said Steve Kraus, Partner, Bessemer Venture Partners. "Bessemer is proud to back a company with a mission to ultimately make it easier and more cost effective for patients to get the treatment they need."

In addition to Kavazovic, the health technology start-up was co-founded by Tesh Khullar, who serves as the company's President. Kavazovic and Khullar are former Flatiron Health executives, where they gained experience working closely with hundreds of oncology clinics. The company's Chief Pharmacy & Operating Officer is Denali Cahoon, PharmD, who is a former executive at Trellis Rx.

"The antiquated pharmacy systems developed decades ago inhibit coordinated patient care and increase costs. The current system also prevents patients from choosing where they can get their medically prescribed life-sustaining therapies," said Tesh Khullar, President and a co-founder. "We started House Rx to make the medically integrated dispensing model the new normal in specialty pharmacy. With the right technology, and the right distribution partners, we can re-establish the partnership between physicians and pharmacists that brings a new level of transparency and patient care."

House Rx's technology platform helps prescribers and pharmacists collaborate more effectively via one integrated system. Built based on in-depth feedback from pharmacists and physicians, the platform is designed specifically for the management of specialty medication, and includes built-in analytics to enable continuous improvement in operational efficiency and quality of care.

The specialty medical practices that have already partnered with House Rx include Care Oncology Center, California; Sarcoma Oncology, California; Arthritis Northwest Washington; and Northwest Medical Specialties, Washington.

About House Rx
House Rx is a technology-enabled service company focused on making specialty medication more accessible and affordable. We do so by helping clinics dispense specialty medications to their patients in a medically-integrated way using pharmacist expertise and modern technology. By helping physicians and pharmacists collaborate on patient care, we're able to improve patient outcomes, lower the cost of care, and create a better experience for patients and their caregivers.


Healthcare sector throughout the globe presents a contrasting landscape. On one hand, powered by the latest technology such as the Internet of Things and Artificial Intelligence, diagnostic, treatment, and care solutions have improved, and on the other hand, ageing population, rise in the cost of medical care, and increase in chronic diseases are posing a greater threat.


Healthcare sector throughout the globe presents a contrasting landscape. On one hand, powered by the latest technology such as the Internet of Things and Artificial Intelligence, diagnostic, treatment, and care solutions have improved, and on the other hand, ageing population, rise in the cost of medical care, and increase in chronic diseases are posing a greater threat.

Related News


Imbio and Riverain Technologies Collaborate to Provide a Comprehensive AI-Powered Lung Health Solution

Imbio | May 19, 2021

Imbio, a leading medical imaging artificial intelligence (AI) provider for chronic lung and cardiothoracic diseases, and Riverain Technologies, a leader in clinical AI for lung nodules, have announced a collaboration to provide clinicians, health systems, and radiology facilities with a more comprehensive lung health solution through a joint offering of their FDA cleared AI tools. Riverain and Imbio also have scientifically proven thoracic imaging products that use machine learning and deep learning to assist clinicians in diagnosing lung diseases using digital data-driven tools. Imbio is the first company that can provide fully automated quantitative analysis and 3D visualization of lung diseases like COPD, emphysema, and Interstitial Lung Diseases. The company's patented Functional Lung Density Analysis (LDAf) algorithm helps to visualize the components of COPD by providing a complete mapping of normal lung, air-trapping, and regions of chronic low density in a combined image, while their Lung Density Analysis Inspiration (LDAi) algorithm aids in the quantification and visualization of emphysema in low dose CT scans.LDAi also produces personalized reports for face-to-face patient communication, which can be used to educate people about their lung problems and help them quit smoking. ClearRead solutions from Riverain Technologies include intelligent, enterprise-wide, standard-of-care AI tools for the early and effective diagnosis of lung nodules. Using patented suppression technology in thoracic CT and X-ray images, their ClearRead suite greatly enhances a clinician's ability to reliably and effectively diagnose disease – for earlier, more efficient detection of lung abnormalities. About Riverain Technologies Riverain is committed to detecting lung disease as soon as possible. The opportunities for machine learning and software solutions in healthcare, according to Riverain, are at an all-time high. Never before has there been such a great opportunity to 'do more for less.' They believe that tools with increasing levels of intelligence can make decision-making easier, resulting in better patient outcomes. About Imbio Imbio is a leader in fully automatic AI image analysis for pulmonary and cardiothoracic conditions, both acute and chronic. Imbio's technologies improve physician productivity and patient care by transforming how patients are discovered, diagnosed, and treated. Imbio's solutions are completely automated, have received regulatory approval, and are available through their global partners.

Read More


Microsofts Authparency for Startups to Remove Contact from the Earlier Approval Process and Wipeout Obstructions to Medical Care

OncoSpark | April 18, 2022

Authparency, an effort of OncoSpark Inc., a leader in value-based technology-enabled services, is focused on automating and improving the prior authorization process. Authparency, which is based on more than a decade of clinical and administrative prior authorization information, has been selected for the Microsoft for Startups Founders Hub, which will allow it to continue to develop and use its technology. The platform was designed with features and modules that take advantage of subject matter experts and interoperability for medical procedures as well as medications and infusions. Microsoft for Startups offers together with the technology, direction, and support we need to continue to have a strategic and fundamental impact on the value of patients and healthcare receipts. "This initiative serves as the foundational catalyst that is needed to harness confidence and speed in our solution, which is critical for patients and providers as we design less restrictive value-based therapeutic pathways," stated Jordan Johnson, Chief Innovation Officer of OncoSpark. Authparency was developed with the help of more than 100 doctors, patient advocates, benefit navigators, and other stakeholders who see the importance of greater patient, payer, and provider alignment. The platform's data is affecting pharma, industry, and health policy in terms of openness and access to care, as well as aiding clinical decision-making. "The onerous prior authorization requirements burden practices with a variety of barriers, including issues submitting documentation through disparate health plan web portals. This remains a major problem in healthcare as we are seeing an increase in those seeking specialty care and an even greater increase in barriers to this care. By standardizing the process and creating relational data, we are able to work directly with payers and pharmaceutical companies to drive optimization and value." Manish Jain, a co-founder of OncoSpark Jordan Johnson added, "The commitment and values of the Microsoft and Oncospark teams allow us to serve communities, patients, and providers to reduce barriers in a dynamic and changing environment." Bringing tracking, payer connectivity, direct submission, insurance validation, HUB enrollment, and assistance pathways into one integrated platform ensures viability, sustainability, and optimal resource allocation for providers and practices that operate on razor-thin margins and struggle with staffing.

Read More


Change Healthcare Joins OptumInsight to Advance a More Modern, Information and Technology-Enabled Health Care Platform

Optum | January 07, 2021

Optum, a diversified health services organization and part of UnitedHealth Group (NYSE: UNH), and Change Healthcare (NASDAQ: CHNG), a health care technology pioneer, have consented to join. Change Healthcare will get together with OptumInsight to give programming and information investigation, technology-empowered services and examination, warning and income cycle the executives contributions to help make health care turn out better for everybody. This combination joins two technology and administration organizations zeroed in on serving health care. Their consolidated capacities will all the more adequately interface and rearrange center clinical, managerial and installment measures - bringing about better health results and encounters for everybody, at lower cost. Change Healthcare brings key advances, associations and progressed clinical choice, authoritative and monetary help capacities, empowering better work process and conditional availability across the health care framework. Optum brings current investigation, exhaustive clinical ability, creative innovations and broad involvement with improving operational and clinical execution. “Together we will help streamline and inform the vital clinical, administrative and payment processes on which health care providers and payers depend to serve patients,” said Andrew Witty, President of UnitedHealth Group and CEO of Optum. “We’re thrilled to welcome Change Healthcare’s highly skilled team to create a better future for health care.” “This opportunity is about advancing connectivity and accelerating innovations and efficiencies essential to a simpler, more intelligent and adaptive health system. We share with Optum a common mission and values and importantly, a sense of urgency to provide our customers and those they serve with the more robust capacities this union makes possible,” said Neil de Crescenzo, President and CEO of Change Healthcare. Upon closing, Mr. de Crescenzo will serve as OptumInsight’s chief executive officer, leading the combined organization. Some of the key opportunities to enhance the health care system include: The combined company will help clinicians make the most informed and clinically advanced patient care decisions, more quickly and easily. Change Healthcare brings widely adopted technology for integrating evidence-based clinical criteria directly into the clinician’s workflow, while Optum’s clinical analytics expertise and Individual Health Record can strengthen the evidence base needed to deliver effective clinical decision support at the point of care. This can ensure appropriate sites of care and consistently achieve the best possible health, quality and cost outcomes. Complexities across the health system result in significant levels of administrative waste. The combined company will be well positioned to make health care simpler, more efficient and more effective. A key opportunity is to enhance with insights drawn from billions of claims transactions using Change Healthcare’s intelligent health care network, combined with Optum’s advanced data analytics. This will support significantly faster, more informed and accurate services and processing. Change Healthcare’s payment capacities combined with Optum’s highly automated payment network will simplify financial interactions among care providers, payers and consumers and accelerate the movement to a more modern, real-time and transparent payment system. This will ensure physicians get paid more quickly, accurately and reliably, and provide consumers the same simplicity and convenience managing their health care finances they experience with other transactions. Change Healthcare brings deep patient communication capabilities, engaging more than 200 million unique individuals each year. Integrating these engagements with people’s health financial benefits will make it simpler for consumers and enhance alignment with incentive programs which reward healthy behaviors. “Change Healthcare has made significant progress executing its strategic objectives, including advancing innovation, accelerating growth and improving the effectiveness of the U.S. health system,” said Howard Lance, Chairman of the Board of Directors of Change Healthcare. “We are delighted to have in Optum a partner that shares a common vision of creating a better future for health care for the people and communities we serve and see this combination as in the best interests of all of our stakeholders.” The arrangement requires the securing of Change Healthcare's basic stock for $25.75 per share in real money and is relied upon to shut in the second 50% of 2021, subject to Change Healthcare investors' endorsement, administrative endorsements and other standard shutting conditions. Private value finances associated with The Blackstone Group, which own around 20% of the regular supply of Change Healthcare, have consented to cast a ballot the offers they control for the combination. The securing is relied upon to be accretive to UnitedHealth Group's net and changed income per share by around $0.20 and $0.50 individually in 2022, progressing emphatically in ensuing years, comprehensive of speculations to quicken technology, framework and item coordination and advancement exercises to all the more rapidly convey the estimation of this combination to all health care framework partners. Changed income reject from net profit just the after-charge non-money amortization cost relating to obtaining related immaterial resources. About Optum Optum is a leading information and technology-enabled health services business dedicated to helping make the health system work better for everyone. With more than 190,000 people worldwide, Optum delivers intelligent, integrated solutions that help to modernize the health system and improve overall population health. Optum is part of UnitedHealth Group (NYSE: UNH). About Change Healthcare Change Healthcare (NASDAQ: CHNG) is a leading independent healthcare technology company, focused on accelerating the transformation of the healthcare system through the power of the Change Healthcare Platform. We provide data and analytics-driven solutions to improve clinical, financial, administrative, and patient engagement outcomes in the U.S. healthcare system.

Read More